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Background: Management of acute sore throat poses a significant burden on UK general practices, with almost
10% of registered patients attending their GP with sore throat every year. Nearly half of all patients presenting with
acute sore throat are treated with antibiotics, despite their limited effect. In a recent systematic review we
demonstrated that a single dose of steroids reduced the severity and time to resolution of sore throat. However, all
of the trials included looked at the use of steroids alongside antibiotics and only one was in a primary care setting.
This trial aims to assess the efficacy and cost-effectiveness of a single oral dose of corticosteroids on symptoms of
sore throat in patients receiving either a delayed antibiotic prescription or no antibiotics at all in UK primary care.
Methods/Design: A double-blind, two arm, randomized, placebo controlled trial in adults (≥18 years of age) presenting
to primary care with acute sore throat (<seven days). Participants are recruited on the day of presentation to their GP
practice. GPs or nurses assess eligibility, record baseline clinical features and obtain a throat swab for bacterial culture.
Participants are being randomized to treatment arms at a ratio of 1:1. Treatment arms will be stratified according to
whether patients are being given a delayed antibiotic prescription or no antibiotic prescription and by recruiting centre
(Oxford, Bristol or Southampton). Outcome data is being collected at 24 and 48 hours via text message or telephone call,
from days 0 to 7 using a patient symptom diary and at one month via a GP notes review.
Discussion: This will be the first randomized controlled trial of oral corticosteroids in adults presenting to primary care
with sore throat in the UK, and the first to examine the clinical and cost-effectiveness of oral corticosteroids for the
treatment of sore throat in the absence of antibiotics.
Trial registration: This trial is registered with Current Controlled Trials on 26 March 2013, registration number:
ISRCTN17435450.
Keywords: Sore Throat, Steroid, Antibiotics, Delayed Antibiotic Prescription, Dexamethasone, Same Day Recruitment,
Adults, Randomized, Placebo-controlledBackground
Epidemiology, costs and current management of sore throat
Sore throat is a common complaint and is a frequent
reason for patients to attend primary care. In 2006, nine
patients consulted a general practitioner (GP) with sore
throat for every 100 patients registered [1]. Tonsillitis
was diagnosed in 3 out of 100 patients registered, and of* Correspondence: gail.hayward@phc.ox.ac.uk
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unless otherwise stated.these, 91% received antibiotics. Half of the remaining
cases, coded as sore throat or pharyngitis, also received
antibiotics. Prescribing rates for sore throat are clearly
disproportionately high, especially since treatment of
sore throat with antibiotics provides only modest symp-
tomatic benefit [2,3].
Antibiotic resistance in general is still increasing
across Europe and represents a growing threat to the
effectiveness of antibiotics [4-6]. Although prescribing
rates have fallen for patients presenting with the com-
mon cold, a similar decrease has not been noted for soretd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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native symptomatic treatments, resulting in a prescribing
‘vacuum’.
The lost productivity associated with tonsillitis has
been estimated at £190 per episode [7]. The weekly UK
incidence of patients presenting to their GP with sore
throat averages at 60 per 100,000 in the current popu-
lation. Extrapolating from this, we might expect a cost
of almost £6 per person per year in lost productivity
alone (equating to £370 million at 2010 population
figures), in addition to an estimated £60 million cost in
GP consultations [8].
Rationale for testing the effectiveness of corticosteroids
in sore throat
Corticosteroids may offer an alternative symptomatic
treatment for sore throat. They are known to inhibit
transcription of the pro-inflammatory mediators in airway
endothelial cells which are responsible for pharyngeal in-
flammation and ultimately symptoms of pain [9]. Steroids
are beneficial in other upper respiratory tract infections
such as acute sinusitis, croup, and infectious mononucle-
osis [10-13]. Short courses of even high-dose oral steroids
are considered to be safe, in the absence of any specific
contraindications [14].
A systematic review and meta-analysis of randomized
controlled trials assessing the benefit of oral corticoste-
roids in sore throat [15,16] identified eight eligible trials.
The review found that a single dose of oral or intramus-
cular dexamethasone increased the likelihood of complete
resolution of pain at 24 hours by more than three times
(relative risk 3.2 (95% CI 2.0 to 5.1; P <0.001), absolute risk
reduction 27% (95% CI 17 to 36%), number needed to
treat 3.7 (95% CI 2.8 to 5.9)). The mean time to onset of
pain relief was reduced by more than 6 hours (95% CI 3.4
to 9.3; P <0.001). However, all of the included trials
compared steroids to placebo in addition to oral antibi-
otics. Furthermore, only one of the trials (in Israel) re-
cruited patients presenting to primary care. We have
searched the International Controlled Trials Register to
confirm there are no similar trials currently being con-
ducted or registered.
Justification for treatment dose and method
The dose of oral corticosteroid used in the majority of
previous trials in adults was a single dose of 10 mg of
dexamethasone or the equivalent dose of prednisolone,
either orally, or intramuscularly, or both. Those trials in-
cluded children up to the age of 18-years-old and used
10 mg of dexamethasone as the maximum dose. Our
systematic review found no difference in the effect of
oral compared to intramuscular administration of cor-
ticosteroid. Therefore this trial is using a single dose
of 10 mg of oral dexamethasone as the dose mostcommonly found to be effective and the treatment method
causing the least discomfort.
Known and potential risks to human participants
Long-term steroid use is known to be associated with an
array of systemic side effects [17]. However, in the ab-
sence of specific contraindications [17,18], a short (up to
1 week) course of high-dose steroids is considered to be
safe and associated with few side effects [19]. Our sys-
tematic review found no difference in either serious ad-
verse events or all adverse events, relapse or recurrence
rates between participants receiving corticosteroids and
those receiving placebo [15].
The prospect of achieving rapid symptomatic relief
with a single dose of oral steroids has positive implica-
tions: improving patient treatment options, reducing
unnecessary antibiotic prescriptions and reducing the
economic burden of sore throat. However, evidence is
required for the clinical and cost-effectiveness of oral
steroids in sore throat in the absence of antibiotics and
in a primary care population. We are therefore con-
ducting a randomized double-blind trial comparing a
single dose of oral dexamethasone to placebo in adults
aged 18 years or over presenting to UK primary care




The primary objective of the trial is to investigate if, in
adults ≥18 years presenting to primary care with acute
sore throat, the use of a single dose of oral dexametha-
sone leads to increased speed of resolution or improve-
ment in symptoms compared with placebo.
The trial has several secondary objectives. Firstly, to
investigate whether dexamethasone compared with pla-
cebo leads to increased resolution or improvement in
symptoms in those patients who have not been pre-
scribed antibiotics. Secondly, to investigate whether
dexamethasone compared to placebo will, in those
patients offered a delayed antibiotic prescription, re-
duce the number of patients taking antibiotics for their
sore throat within seven days. Thirdly, to investigate
whether a single dose of oral dexamethasone compared
to placebo will: reduce time away from work or educa-
tion within seven days, not increase the incidence of
hospital admission with complications related to sore
throat (such as peritonsillar abscess) within 28 days,
not increase repeat attendance at the GP within 28 days
with symptoms or complications of sore throat, and be
cost-effective. Fourthly, to assess predictors of response
to corticosteroids including existing severity scores
(FeverPAIN score and Centor score), baseline factors and
positive bacterial throat swab.
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The trial is a two arm, individually randomized, double-
blind trial comparing a single dose of 10 mg oral dexa-
methasone with placebo in adults aged 18 years or over
presenting to primary care with sore throat. The trial
requires a single visit to the GP from each participant
and a one-week period of participant involvement from
the point of randomization and treatment. See flow
chart (Additional file 1). The trial will be a multicenter
trial based at general practices in Oxford, Bristol and
Southampton in England, UK.
Primary and secondary endpoints and outcome measures
Primary outcome
The primary outcome of this trial is the direct report by
the patient of presence or absence of complete reso-
lution of sore throat at 24 hours by either text message
or telephone.
Secondary outcomes
The trial has several secondary outcomes which include:
direct report by those patients who have not been pre-
scribed antibiotics of presence or absence of complete
resolution of sore throat at 24 hours by either text mes-
sage or telephone, and report of presence or absence of
complete resolution of sore throat at 48 hours by either
text message or telephone contact. Additionally we will
record for the seven days after treatment is adminis-
tered: time to onset of pain relief (in hours), time to
complete symptom resolution (in hours), report of diffi-
culty swallowing and pain on swallowing, the duration
of moderately bad symptoms recorded by validated
symptom diary, the change in ratings of sore throat pain
and pain on swallowing by visual analogue scale, the up-
take of delayed antibiotic prescription and any time
missed from work or education.
Furthermore we will record the severity of symptoms
in the two to four days after seeing a GP based on the
symptom diary, any attendance at GP practices, Emergency
Departments, or out-of-hours centers within 28 days with
symptoms or complications associated with sore throat
such as peritonsillar abscess, any hospital admission with
related complications of sore throat within 28 days, use of
over-the-counter medications and prescription medica-
tions (including, if delayed antibiotics are taken, whether
the course is completed and whether any other antibiotics
were taken) in the first seven days and cost-effectiveness
measures which include incremental cost, EuroQol EQ-
5D-5L score change in seven days and impact on usual
activities over most recent seven days
Inclusion criteria
Trial participants will be anyone aged 18 years or over
presenting to primary care with acute sore throat whichis judged by the clinician to be infective in origin, whose
onset of symptoms has been within seven days of pres-
entation and has the capacity and willingness to complete
trial documentation.
Exclusion criteria
The participant may not enter the study if any of the fol-
lowing apply:
They are a female participant who is pregnant, lactating
or planning pregnancy during the course of the study, they
have had recent (<one month) use of inhaled or oral corti-
costeroids or a recent (<one month) adenotonsillectomy.
Participants will be excluded if they are currently or
recently (<14 days) taking antibiotics, there is a clear al-
ternative diagnosis such as pneumonia or they have a
known immune deficiency (such as HIV, active chemo-
therapy or advanced cancer), are scheduled elective sur-
gery or other procedures requiring general anaesthesia
during the next seven days, are terminally ill, or have
symptoms or signs suggesting that hospital admission is
required (such as being completely unable to swallow,
very systemically unwell or peritonsillar abscess).
They are also excluded if the patient is judged by the
GP to require immediate antibiotics, has a history of se-
vere affective disorders including steroid-induced psychi-
atric illness, is currently taking any medication on the
British National Formulary (BNF) listed contraindica-
tions to oral steroids or has existing symptoms that are
also side effects of oral steroids or if the patient is taking
other interacting medication (for example phenytoin and
anti-coagulants). Clinicians are asked to use the BNF
and their clinical prescribing systems to check for inter-
actions for all patients.
Further to this patients are excluded if they have a
known dexamethasone allergy or if they have any other
significant disease or disorder which, in the opinion of
the investigator, may either put the participants at risk
because of participation in the study, or may influence
the result of the study or the participant’s ability to par-
ticipate in the study.
If the patient has been involved in another clinical trial
of an investigational medicinal product in the last 90 days
or any other research within the last 30 days, the recruit-
ing primary care site is not the patients usual practice if
the patient is not expecting to still be with the primary
care site in one month ( temporary residents), they have
previously participated in the TOAST trial the patient is
unable to be randomized by the end of the (working) day
of presentation or they have a requirement for a live vac-
cine in the next seven days they will also be excluded.
Expenses and benefits
Healthcare visits in addition to normal care are not an-
ticipated, nor does the trial offer any other payment for
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penses are incurred due to an extra visit to the GP for
the baseline trial assessment these expenses will be cov-
ered. Trial medication is provided free of charge, but
participants will have to pay for their antibiotic prescrip-
tion, if one is given. However, participants who return a
completed symptom diary to the Primary Care Clinical
Trials Unit (PC-CTU) are being sent a £10 gift card as




The participant must personally sign and date the latest
approved version of the informed consent form before
any study specific procedures are performed. Written
and verbal versions of the participant information sheet
and informed consent are presented to participants by
the responsible clinician detailing no less than the exact
nature of the study, the implications and constraints of
the protocol, the known side effects and any risks in-
volved in participation. It is clearly stated that the par-
ticipant is free to withdraw from the study at any time
for any reason without prejudice to future care, and with
no obligation to give the reason for withdrawal.
The participant receives the participant information
sheet at their initial consultation with their GP, and if
eligible and interested, is referred on to a baseline trial
assessment with a recruiting clinician for full consent
procedures and trial procedures. This gives participants
the opportunity to consider the information, and to
question the recruiting clinician, their GP or other inde-
pendent parties to decide whether they will participate
in the study. Written informed consent is then obtained
by means of participant dated signature and dated signa-
ture of the person who presented and obtained the in-
formed consent. The person who obtained the consent
must be suitably qualified, experienced and trained in
line with the Medicines and Healthcare Products Regu-
latory Agency, MHRA requirements, and have been
authorized to do so by the Chief Investigator. A copy of
the signed informed consent will be given to the partici-
pants and the original signed form will be retained at
the study site.
Screening and eligibility assessment
The primary care site gives adults presenting with sore
throat a participant information sheet which details what
is involved in trial participation. During the initial con-
sultation the primary care clinician (referred to from
now onwards as the responsible clinician) discusses trial
participation and screens the participant using the inclu-
sion and exclusion criteria. The responsible clinician
may be a triage nurse if the GP judges that they arecompetent to perform the baseline assessment and eligi-
bility screening. Any patient who is not eligible to par-
ticipate or declines to participate will be recorded on the
screening log with reasons for ineligibility or declining
(if known) and have no further involvement in the trial.
The responsible clinician completes their routine clin-
ical management, and at the clinician’s discretion will
offer a delayed antibiotic prescription, to be collected by
the patient either from the recruiting clinician at their
subsequent baseline trial assessment, or from the recep-
tion of the GP practice according to the standard proced-
ure of the practice. The delayed antibiotic prescription will
be accompanied by: reassurance that antibiotics are often
not needed immediately and information about the disad-
vantages of antibiotics, information about the natural his-
tory of sore throat and advice to use regular pain relief,
instructions for the antibiotics to be collected and used
after three to five days if the patient feels their symptoms
are not starting to improve, or sooner if their symptoms
are getting significantly worse and a brief information leaf-
let containing instructions and explanation regarding a de-
layed prescription to reinforce these points.
Baseline assessments
Within six hours of the initial consultation, potentially
eligible patients undergo a baseline trial assessment with
a primary care clinician allocated by the practice to re-
cruit patients (from here on known as the recruiting
clinician).
At this meeting a full trial explanation is given and
time allowed for the participant to ask any questions,
and then written consent is obtained. The recruiting
clinician uses a secure, web-based data collection plat-
form (hosted by the University of Oxford) to enter the
participant’s baseline data and confirm eligibility using a
standard computer within the GP practice. Once the eli-
gibility is confirmed, randomization proceeds.
The recruiting clinician gives the participant standard-
ized instructions regarding how to complete the symp-
tom diary and other response forms and observes the
participant taking the trial medication (oral corticoster-
oid or placebo). The recruiting clinician records the par-
ticipant’s contact details for the 24- and 48-hour data
collection contacts. Those participants for whom the GP
has deemed a delayed antibiotic prescription is appropri-
ate are provided with the prescription if this is the stand-
ard procedure of the practice.
The recruiting clinician takes a bacterial throat swab.
These are being analyzed for streptococcus A, C and G.
The participant’s date of birth, sex and the participant
trial ID number are being used as identifiers for these
swabs. In the rare event that an unusual and potentially
dangerous pathogen is detected by bacterial throat
swab, and the medically qualified Chief Investigators
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these results.
Baseline case report form data items are:
Socio-demographic factors which will include: age,
gender, smoking history and paid work or education.
Medications which will include: decision whether or not
to offer delayed antibiotic script and if offered, type of
dose, dosing regimen and duration of antibiotics pre-
scribed as well as whether the practice left the script for
collection at reception or gave it to the patient at the
baseline recruitment meeting and any other advised
treatment. Symptoms which will include: the duration of
sore throat and painful swallowing and the presence or
absence of cough, hoarse voice, coryza and fever in last
24 hours, all of which use a validated scale, where ‘None’
is equal to absence of and ‘Slight’ ‘Moderate’ and ‘Severe’
are equal to presence of. Clinical examination findings
which will include the confirmation of: the presence of
pharyngeal inflammation, the presence of tonsils, the
presence of inflamed tonsils, the presence of purulent
tonsils, the presence of cervical lymphadenopathy, the
presence of tender cervical lymphadenopathy, the partic-
ipants temperature and type of thermometer used for
measuring. Patient-completed items which will include:
ratings of throat soreness, pain on swallowing and diffi-
culty swallowing using visual analogue scales, baseline
severity ratings using symptom diary and completion of
the EuroQol EQ-5D-5L instrument [20].
All these procedures happen according to the schedule
of procedures; see Additional file 2.
Randomization and codebreaking
Randomization was performed by the Oxford PC-CTU and
is stratified by centre (Oxford, Bristol and Southampton)
and by receipt or not of delayed antibiotic prescription
using a block randomization with variable block size.
An independent statistician based in the Department of
Primary Care Health Sciences at the University of
Oxford generated the randomization schedule. They
produced a list of four-digit unique medication IDs;
these were printed on the medication labels in vari-
able block sizes stratified as above. This statistician is
not involved in any other aspect of the trial.
Each site is initially allocated to hold two sets of two
to three packs of pre-randomized medication, one set for
those who are given an antibiotic prescription and one set
for those who are not. They then liaise with their local
centre (the centre responsible for setting up the site) when
they have allocated their existing packs to trial participants
and reallocation of medication, if deemed necessary, only
occurs within the same centre and same subgroup of par-
ticipants, having delayed antibiotic prescription or not.
They also receive an equal number of participant folders
containing unique participant trial IDs.The recruiting clinician allocates the patient one
pack of medication from the appropriate set of pre-
randomized medications and they record the unique
medication ID on the baseline case report form, CRF.
The recruiting clinician informs their local study centre
(Oxford, Bristol or Southampton) which medication has
been allocated to which participant trial ID and the local
study centre keeps a log of all allocated medication and
participant trial IDs. The recruiting clinician also enters
the participant trial ID on the drug allocation log on site
against the allocated medication ID.
The trial investigators have reviewed the clinical safety
of the study and do not feel that an emergency 24-hour
unblinding service is required. The only major adverse
event where clinical management might be affected by
this knowledge is anaphylaxis, and, as the medication is
taken by the participant under observation in the general
practice during working hours, this will be managed in
hours if required. In addition an independent clinician
has confirmed that clinical care offered to a patient pre-
senting with an adverse event or serious adverse event,
AE/SAEwould not be influenced by knowledge of which
study arm they were in. Participants remain in the prac-
tice for 10 minutes after the medication has been taken
to ensure that any immediate reaction can be treated. In
the very rare event that analysis of the bacterial throat
swab reveals an unusual and potentially dangerous
pathogen; the Chief Investigator will be contacted to as-
sess the need for emergency unblinding and informing
the participant’s practice. This information will only be
received, and the practice contactable, in office hours.
A standardized procedure for emergency unblinding is
available. The codes will only be broken in case of a
major adverse event (such as anaphylaxis or admission
to hospital with a life-threatening illness (for example
septicemia, meningitis, severe pneumonia requiring ITU
admission or death)). The randomization code is stored
electronically on a secure password-protected drive and
access is restricted to the independent statistician. If
unblinding is deemed necessary the Chief Investigator or
designated representative will inform the independent
statistician to notify the relevant responsible clinician of
the treatment allocation for the relevant participant. The
trial investigators will not be informed which arm of the
trial the participant was allocated to. If randomization of
a participant is unblinded during the study then data for
that participant, if available, will be included in the
intention-to-treat analysis.
The procedures for code break at the end of the trial
will be as follows: once all the data queries have been
resolved, a blind data review meeting will be initiated in-
volving the trial statistician, the data manager, the trial
manager and the Chief Investigator. All protocol viola-
tions will be reviewed and a list of study populations for
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Investigator and the statistician. At this point, the data-
base will be locked and decoding of the allocation will
be allowed.
Subsequent assessments
Following the baseline trial assessment participants
complete a symptom diary reporting upon the reso-
lution of symptoms and time to onset of pain relief,
and rating their pain on a visual analogue scale every
day for seven days on paper. As well as recording the
severity and duration of their symptoms, this also in-
cludes providing information about NHS resource use,
out-of-pocket expenditure, use of over-the-counter and
prescription medications and time off work and/or edu-
cation or foregone leisure time. Within the symptom
diary we also ask participants to complete the EuroQol
EQ-5D-5L instrument [20] daily for seven days following
study entry.
Participants are telephoned or texted at 24 and
48 hours to support collection of the primary outcome
and secondary outcomes. As preference this contact will
be made via text message because of the greater accur-
acy with times and standardization. They are additionally
telephoned in the first 96 hours if required to support
and encourage completion of the symptom diary; they
will also receive a text message at day four and day nine
to encourage completion of the symptom diary and to
remind them to return it to the PC-CTU. Follow-up is
being undertaken by research coordinators at all three
centers. Follow-up continues for seven days from the
initial day of recruitment. Participants are asked to re-
port in the diary any use of medications, including
whether they obtained and completed the delayed anti-
biotic prescription. If participants do not complete the
symptom diary over the seven days we send them a
short questionnaire after this in order to collect informa-
tion for key secondary outcomes relating to the first four
days after taking the trial medication and, if needed, they
are telephoned in order to help them complete the ques-
tionnaire. All paper diaries and questionnaires are sent
back to the respective centre in pre-paid envelopes.
A review of the primary care notes is undertaken
by the recruiting primary care site one month post-
randomization, to record repeat presentation to a GP,
Emergency Department or out–of-hours primary care
centre with symptoms or complications of sore throat,
hospital admissions and use of prescription medications.
Baseline information about past medical history and
acute and repeat medication usage is also collected.
Definition of end of trial
The end of trial will occur once the primary outcome
data has been collected for all patients and the onemonth follow-up notes review of the final participant
has been performed.
Discontinuation and withdrawal of participants from
study treatment
Each participant has the right to withdraw from the
study at any time. In addition, the investigator may dis-
continue a participant’s involvement in the study at any
time if the investigator considers it would be harmful to
keep a participant in the study. The reason for with-
drawal will be recorded in the CRF.
If the participant is withdrawn due to an adverse
event, the investigator will arrange for follow-up visits or
telephone calls until the adverse event has resolved or
stabilized, or until the end of the study when participant
care will return solely to the GP. The participant’s data
will be retained in the trial for the purpose of intention-
to-treat analysis unless consent to do so is specifically
withdrawn. This is in order to safeguard the validity of
the data set. If a participant is found to be ineligible after
they have been randomized then they will be removed
from the trial. Their data will also be removed from the
intention-to-treat analysis.
Source data
Source documents are original documents, data and re-
cords from which participants’ CRF data are obtained.
These include, but are not limited to, general practice
medical records (from which medical history and previ-
ous and concurrent medication may be summarized into
the CRF, as well as follow-up data at one month). CRF
entries will be considered source data if the CRF is the
site of the original recording (there is no other written
or electronic record of data). In this study the CRF is be-
ing used as the source document for the documentation
of inclusion and exclusion criteria, and baseline assess-
ment information. Symptom diaries and telephone calls
recorded onto CRFs are considered source data. All doc-
uments are stored safely in confidential conditions. On
all study-specific documents other than the signed con-
sent the participant will only be referred to by their
study participant ID.
Treatment medication
Description of study treatment
The study treatment is a single 10 mg dose of dexa-
methasone taken orally. The dose takes the form of five
2 mg dexamethasone tablets over-encapsulated into a
single capsule and an over-encapsulated placebo identi-
cal in size, colour and taste. The drug acquisition, over-
encapsulation, packaging and labelling was performed by
Nottingham University Hospitals NHS Trust.
The labelling of medication packs conforms to Annexe
13 (GMP) and Article 13.3 of European Commission
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the clinical trial team and provided to the manufacturer
by the Chief Investigator. Each medication pack label is
printed with a unique medication ID number to ensure
dexamethasone and placebo medicine packs are indistin-
guishable and thus maintain allocation concealment.
This randomized medication ID forms the identifier on
the open code-break document sent with each delivery
of medication packs to the University of Oxford PC-
CTU. The medicines were received from the manufac-
turer and are stored securely by the clinical trials unit.
The trial centers are responsible for supplying the
medication packs to the GP practices in their area, four
to six packs at any one time, so that clinicians can draw
from their allocation as recruitment proceeds. Trial cen-
ters keep a log of medication packs sent to a GP prac-
tice, with all medication packs signed for on receipt at
the GP practice. Sites liaise with their local centre when
more packs are required, and the local centre then liaises
with the Oxford centre to send a further block to the
local centre. At all times the medicines will be stored at
room temperature, in line with the summary of product
characteristics, SmPC. The study drug and placebo can
be stored below 25°C and out of direct sunlight and are
kept securely in the Oxford PC-CTU and on site, with
controlled access by site trial staff. A formal risk assess-
ment considering all the potential risks involved in the
distribution of the trial medication will be written along-
side a standard operating procedure detailing the exact
procedure for the handling of all trial medication to en-
sure that any associated risks will be minimized.
Compliance with study treatment
The participant is observed taking the single dose of
study medication once they have provided full informed
consent.
Accountability of the study treatment
The study medication is supplied by Nottingham Uni-
versity Hospitals NHS Trust to the clinical trials unit.
All movements of study medication between Notting-
ham University Hospitals NHS Trust and clinical trials
unit are documented. The clinical trials unit will supply
the allocated drugs to the local centers who distributed
these out to the sites in their area. The clinical trials unit
will keep logs of all medication IDs and where each drug
is sent to, local centers will keep logs of all drugs allo-
cated to them and the GP practices will keep local drug
accountability logs, including drug allocation logs.
In the event that medication needs to be redistributed,
a drug redistribution log must be completed to docu-
ment the unique medication ID and must include a
minimum of one release signature (origin site staff ),
one transporter signature (PC-CTU staff ) and onereceiving signature (new site staff ), with approval from
the MHRA.
Site-specific procedures will be followed in relation to
disposing of and arranging for destruction of expired
trial medication. Standard GP site procedures should be
followed and the drug destruction log should be com-
pleted with the following details: date, unique medica-
tion ID, expiry date, quantity to be destroyed (number of
tablets) and staff initials to confirm destruction.
Concomitant medication
Throughout the study the responsible clinician may
prescribe any concomitant medications or treatments
deemed necessary to provide adequate supportive care
except for those listed in the exclusion criteria. If
these are required, the participant will stay in the trial
for purposes of intention-to-treat analysis. Any medi-
cation taken during the study other than the study
medication will be recorded in the symptom diary or
noted on notes review.
Post-trial treatment
Following the single dose of oral dexamethasone partici-
pants continue normal medical care by their GP.
Safety reporting
Definitions
An adverse event (AE) or adverse experience is any un-
toward medical occurrence in a patient or any abnormal
result from a clinical investigation in participants who
have been administered a medicinal product,which does
not necessarily have to have a causal relationship with
this treatment (the study medication). An AE can there-
fore be any unfavorable and unintended sign (including
an abnormal laboratory finding), symptom or disease
temporally associated with the use of the study medica-
tion, whether or not considered to be related to the
study medication. An adverse reaction (AR) will be
defined as all untoward and unintended responses to a
medicinal product related to any dose. The phrase
‘responses to a medicinal product’ means that a causal
relationship between a study medication and an AE is at
least a reasonable possibility - the relationship cannot be
ruled out. All cases judged by either the reporting med-
ically qualified professional or the Sponsor as having a
reasonable suspected causal relationship to the study
medication qualify as adverse reactions. A serious ad-
verse event (SAE) will be defined as any untoward
medical occurrence that at any dose results in death,
is life-threatening, requires inpatient hospitalization
or prolongation of existing hospitalization, results in
persistent or significant disability and/or incapacity, is a
congenital anomaly or birth defect or other important
medical events. Other events that may not result in death,
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may be considered an SAE when, based upon appropri-
ate medical judgment, the event may jeopardize the pa-
tient and may require medical or surgical intervention
to prevent one of the outcomes listed above. The term
life-threatening in the definition of SAE refers to an
event in which the participant was at risk of death at
the time of the event; it does not refer to an event
which hypothetically might have caused death if it were
more severe.
To ensure no confusion or misunderstanding of the
difference between the terms serious and severe, which
are not synonymous, the following note of clarification
is provided. The term severe is often used to describe
the intensity (severity) of a specific event (as in mild,
moderate or severe myocardial infarction). The event it-
self, however, may be of relatively minor medical signifi-
cance (such as severe headache). This is not the same as
‘serious’, which is based on participant and/or event out-
come or action criteria usually associated with events
that pose a threat to a participant's life or functioning
as defined in the bullet points above. Seriousness (not
severity) serves as a guide for defining regulatory report-
ing obligations.
A serious adverse reaction (SAR) is defined as an AE
(expected or unexpected) that is both serious and, in the
opinion of the reporting investigator, believed with rea-
sonable probability, to be due to one of the study treat-
ments, based on the information provided. A suspected
unexpected serious adverse reaction (SUSAR) is defined
as an SAR, the nature or severity of which is not consist-
ent with the applicable product information (such as an
investigator’s brochure for an unapproved investigational
product or summary of product characteristics for an
approved product).
Causality
The relationship of each AE to the trial medication must
be determined by a medically qualified individual to be
either related or not related. Related, for these purposes,
requires the AE to follow a reasonable temporal se-
quence from trial medication administration. It cannot
reasonably be attributed to any other cause. Not related,
for these purposes, requires that the AE is probably pro-
duced by the participant’s clinical state or by other
modes of therapy administered to the participant.
Recording and reporting procedures for AEs and SAEs
Dexamethasone is a commonly used medication in a pri-
mary care setting; it has well defined safety profiles and
is being used in this trial for authorized indications. As a
result of this no non-SAEs will be recorded in this study.
All SAEs occurring during the one month participants
are enrolled on the trial will be recorded.A participant may voluntarily withdraw from the trial
due to what he or she perceives as an intolerable AE.
AEs that result in a participant’s withdrawal from the
study will be recorded on the withdrawal form. The rela-
tionship of AEs to the study medication will be assessed
by a medically qualified investigator. The severity of
events will be assessed on the following scale: 1 =mild,
2 =moderate or 3 = severe.
All SAEs must be reported to the PC-CTU within one
working day of discovery or notification of the event.
The PC-CTU will perform an initial check of the report,
request any additional information and ensure it is
reviewed by the Chief Investigator on a weekly basis.
The PC-CTU will also ensure that it is reviewed at the
next Data Monitoring Committee meeting. All SAE in-
formation must be recorded on an SAE forms and faxed
to the PC-CTU. Additional information received for
a case (follow-up or corrections to the original case)
need to be detailed on a new SAE form and faxed to
the PC-CTU.
Data Monitoring Committee
The appointed and independent Data Monitoring Com-
mittee (DMC) conducts a review of all SAEs for the
study reported during the quarter and cumulatively.
They report their findings to the Trial Steering Com-
mittee who in turn report to the Trial Management
Group. The main aims of this review are as follows: to
ensure the safety and rights of each patient in the trial, to
pick up any trends, such as increases in expected and
unexpected events, and take appropriate action, to
monitor the trial data and review and analyze as out-
lined in the statistical analysis plan, systematically or as
requested by the Trial Steering Committee, to seek add-
itional advice or information from investigators where
required, to evaluate the risk, in terms of safety and
ethics, of the trial continuing and take appropriate ac-
tion where necessary and to act or advise, through the
Chairman or other consultant, on incidents occurring
between meetings that require rapid assessment. The
Data Monitoring Committee will also suggest provision of
training specific groups to the Trial Steering Committee
as required.
SUSAR reporting
In collaboration with the University of Oxford’s Clinical
Trials Research Governance (CTRG) the Chief Investiga-
tor will report all SUSARs to the competent authorities
(MHRA in the UK), the research ethics committee con-
cerned and host NHS Trusts. Fatal or life-threatening
SUSARs will be reported within seven days and all other
SUSARs within 15 days. Any additional relevant informa-
tion will be reported within eight days of the initial report.
The Chief Investigator will also inform all investigators
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could adversely affect the safety of participants.
Development safety update reports
In addition to the expedited reporting above, the Chief
Investigator shall submit once a year throughout the
clinical trial on the anniversary of the clinical trial
authorization CTAor on request a development up-
date safety report (DSUR) to the competent authorities
(MHRA in the UK), research ethics committee concerned,
host NHS Trust and Sponsor.
Statistics
Statistical analysis for effectiveness and safety
The primary analysis will be intention-to-treat assuming
no resolution for missing data. The proportion of
complete resolution at 24 hours reported by partici-
pants will be compared between two treatment arms
using a generalized linear regression model for binary
data adjusting for whether participants are prescribed
antibiotics or not. The proportion of complete reso-
lution at 24 hours in those participants who have not
been prescribed antibiotics (on which this trial is
powered) will be compared in the same way.
Logistic regression adjusting for whether participants
are prescribed antibiotics or not will also be performed
to estimate the differences in the proportions of binary
secondary outcomes including reported complete reso-
lution at 48 hours, hospital admission within 28 days,
attendance at GP practice, Emergency Departments, or
out-of-hours centers within 28 days with symptoms or
complications associated with sore throat and uptake
of delayed antibiotic prescription within seven days.
We will explore whether positive bacterial throat swab,
FeverPAIN score, Centor score and other baseline fac-
tors predict response to corticosteroid. Use of over-the-
counter and prescribed medicine other than antibiotics
will be summarized and compared using chi-square
tests.
Mean and standard deviations for reported time to on-
set of pain relief, time to complete resolution of pain,
duration of moderately bad symptoms recorded by vali-
dated symptom diary and time missed from work or
education over the seven days from treatment onset will
be calculated and compared between two treatment
arms using a linear regression adjusting for antibiotic
prescription. We will use data from participants’ diary
on throat pain, pain on swallowing and difficulty in swal-
lowing by visual analogue scale within seven days post-
randomization to calculate areas under the curves as
proxies for a summary measurement and tested for a
difference between two arms using a linear regression
adjusted for antibiotics prescription. All model assump-
tions will be assessed and if data do not conform toassumptions the alternatives will be explored. Symptoms
of interest will be summarized in the proportions and
difference between two treatment arms and 95% CI will
be calculated. Full description of the methods to be used
will be stated in a trial statistical analysis plan.
Health economics analysis
The objective of the economic evaluation is to establish
the difference in costs associated with administering oral
corticosteroids versus placebo for sore throat, and relate
this cost differential to any difference in health benefits
found. The economic evaluation will be undertaken
alongside the trial using widely accepted methods and
will take an NHS perspective. An evaluation from a
wider societal perspective will also be undertaken (as a
component of the cost-consequences analysis) as prod-
uctivity losses and absenteeism are likely to be associated
with sore throat. The costing exercise will identify the
NHS services used.
The economic evaluation has been designed as a cost-
utility analysis, using the participant’s EQ-5D-5L scores
(using a published UK population valuation set and
EuroQoL crosswalk algorithm [21]) as the main eco-
nomic outcome measure. However, the performance and
sensitivity of the EQ-5D-5Lin this participant group and
over such a short follow-up period is uncertain, so its
appropriateness will be investigated by assessing its con-
struct validity and sensitivity to change within the trial.
Due to the likely limitations in using EQ-5D-5L as the
outcome measure, the cost-utility analysis will be sup-
plemented by a cost-consequences analysis using a num-
ber of outcome measures (such as symptomatic days
avoided, EQ-5D-5L disaggregated by domain and days
off work and/or education) as the measure of health
benefit.
Individual-level resource use data is being collected
using resource-use questionnaires and GP records. The
resource use data covers general practice, medications
and hospital services. It also includes a question relating
to time taken off work and/or education and usual activ-
ities due to experiencing a sore throat. These resource
items are being documented by the participants over the
one-week follow-up period and are being collected using
a resource-use questionnaire/diary. In the questionnaire,
participants log NHS services use: the number and type
of GP or practice nurse visits (for example own home,
clinic, practice, out-of-hours, phone), prescription use,
over-the-counter medication use, and hospital Emergency
Department, outpatient or inpatient stays that are directly
related to their sore throat. This health service resource
utilization will be valued using appropriate unit costs ob-
tained from widely used sources, such as the most recent
version of Unit Costs of Health and Social Care [22] and
NHS reference costs.
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instrument developed by the EuroQol group. The symp-
tom and resource-use diary collects participant specific
self-reported time away from work and/or education.
Both are completed at baseline and over the seven day
follow-up period.
Individual costs will be estimated by combining the re-
source use and unit cost data. We will estimate and re-
port mean total costs by trial arm [23] and disaggregate
these according to their burden on primary care and
other care sectors. We will extrapolate our analysis of
health service resource use and costs to explore the po-
tential cost impact of prescribing oral corticosteroids on
a national scale.
To aid decision-makers and to provide a transparency
to our cost-effectiveness analysis we will analyze and re-
port our costs and outcomes by trial allocation in a
disaggregated format. Resource-use and costs will be
reported by NHS sector. Outcomes will be reported in
terms of symptom or pain-free days, EQ-5D-5L (over-
all scores and by domain) and days off work and/or
education.
Mean costs and outcomes will be compared between
the trial arms, using appropriate methods. The primary
cost analysis will compare costs at one-month post-
randomization. In the event of one treatment not dom-
inating another, an incremental cost per quality-adjusted
days (QAD) will be estimated using the EQ-5D-5L. Un-
certainty in the confidence to be placed on the economic
analysis results will be explored through deterministic
and probabilistic sensitivity analysis and presented by es-
timating cost-effectiveness acceptability curves [24]. The
sensitivity analyses will explore uncertainties in the trial
data and analysis methods, including the possibility that
consultation and re-consultation rates for those in the
placebo arm may differ from current standard care.
The number of participants
Based on the results of our systematic review of eight
studies, the average absolute increase in participants
reporting complete resolution of pain at 24 hours with
corticosteroids in addition to antibiotics and analgesia
was 27% [15]. The minimum absolute increase from in-
dividual trials was 18% (11 versus 29%). To achieve this
effect size with 90% power, our conservative estimate of
sample size is 226 patients.
In the UK antibiotics are prescribed to approximately
50% of participants presenting with sore throat [1].
Given that our first secondary objective is to detect a
clinically significant difference in proportions of partici-
pants not having been prescribed antibiotics, we will re-
quire an initial sample of 452 patients. A sample size of
566 allows for loss of up to 20% to follow-up (or 532 for
15% lost to follow-up).Criteria for the termination of the trial
No formal interim analysis is planned to stop the trial
early. Dexamethasone is already licensed and used at this
dosage in a wide variety of disorders. In our systematic
review we found no SAEs reported by any included trial.
No differences were found in all AEs, relapse or recur-
rence rates between participants receiving corticoste-
roids and those receiving placebo, hence we anticipate
that the likelihood of SAEs associated with a single dose
of dexamethasone 10 mg taken orally will be extremely
low. We have therefore not defined any criteria for ter-
mination for safety.
Procedure for accounting for missing, unused, and
spurious data
The percentage of missing outcome data will be com-
pared between two arms and a logistic model will be
used to assess whether covariates significantly predict
dropout. If little is known about the missing mechanism
or there is any concern about validity of the expected
missingness due to treatment failure (assuming no
complete resolution), sensitivity analysis will be per-
formed with plausible non-ignorable missing scenar-
ios and complete cases. These will be detailed in the
separate statistical analysis plan.
During statistical data review and analysis, any anom-
alies in the data will be investigated and discussed with
the Trial Management Group. The data investigation
will be broad and flexible and focus on variability of the
data, consistency, dispersion, outliers, inliers, relation-
ships between variables and relationships over time. The
statistical data review will be fully documented with all
the output dated.
Inclusion in analysis
We will be analyzing our data using the intention-to-
treat principle. All eligible randomized participants will
be included in the analysis, assuming no complete reso-
lution for missing data.
Direct access to source data and documents
Direct access is granted to authorized representatives
from the Sponsor, host institution and the regulatory au-
thorities to permit trial-related monitoring, audits and
inspections. Individual GP practices are required to give
access to the bodies described above and this is outlined
in the Site Agreement.
Quality control and quality assurance procedures
The study is being conducted in accordance with the
current approved protocol, International Conference on
Harmonization Good Clinical Practice, ICH GCP , relevant
regulations and PC-CTU standard operating procedures.
The monitoring will be performed by the PC-CTU Quality
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trial-related site staff have received training in trial proce-
dures and ICH GCP.
Regular monitoring will be performed by the PC-CTU
according to ICH GCP. Data is evaluated for compliance
with the protocol and accuracy in relation to source doc-
uments. Following written standard operating proce-
dures, the monitors will verify that the clinical trial is
conducted and data are generated, documented and re-
ported in compliance with the protocol, ICH GCP and
the applicable regulatory requirements.
An independent Data Monitoring Committee, Trial
Management Group and Trial Steering Committee have
been appointed in line with standard clinical trials unit
procedures. The responsibilities of the Data Monitoring
Committee are to review and monitor the accruing data
to ensure the rights, safety and wellbeing of the trial
participants. They will provide an interim analysis if re-
quested by the Trial Steering Committee. They will
make recommendations to the Trial Steering Committee
about how the study is operating, any ethical or
safety issues and any data being produced from other
relevant studies that might impact the trial. The Trial
Management Group is responsible for the day to day
running of the trial, including monitoring all aspects of
the trial and ensuring that the protocol is being adhered
to. The responsibilities of the Trial Steering Committee
are to provide overall supervision of the trial on behalf of
the Sponsor and the Funder to ensure that it is being
conducted in accordance with ICH-GCP. The Trial
Steering Committee will review the trial regularly, agree
any amendments and provide advice on all aspects of the
trial.
Serious breaches
The Medicines for Human Use (Clinical Trials) Regula-
tions, the UK legislation for the running of clinical trials,
contain a requirement for the notification of ‘serious
breaches’ to the MHRA within seven days of the
Sponsor becoming aware of the breach. A serious
breach is defined as: ‘A breach of GCP or the trial protocol
which is likely to effect to a significant degree – (a) the
safety or physical or mental integrity of the subjects of the
trial; or (b) the scientific value of the trial’.
In the event that a serious breach is suspected the
University of Oxford’s Sponsor’s office, CTRG, should be
contacted within one working day of knowledge. Any
possible serious breach is identified by a member of the
study team; either through site monitoring or audit
visits, or through a whistleblower or a complaint from
within or outside the university. A written record of the
incident will be made and once all necessary information
is gathered the information is reviewed by the rele-
vant staff (such as the Quality Assurance Manager) ifappropriate and recorded on the Serious Breaches
Assessment Form. If considered to be a serious breach
the Chief Investigator will be asked to confirm this deci-
sion and to contact the CTRG. If the event is a serious
breach the CTRG will inform the MHRA within seven
days. Day 1 is considered as the day the incident is con-
firmed as serious by both the team and the CTRG. The
incident will be followed up on by the CTRG in conjunc-
tion with the trials team. The PC-CTU will review all
documentation to see what might have led to the breach
and put in place a corrective action preventative action
plan in collaboration with the CTRG.
Ethics
The Chief Investigator ensures that this study is conducted
in accordance with the principles of the Declaration of
Helsinki. The Chief Investigator also ensures that this study
is conducted in full conformity with relevant regulations
and with the ICH Guidelines for Good Clinical Practice
(CPMP/ICH/135/95) July 1996, including training in GCP
for clinicians as required.
The protocol, informed consent form, participant in-
formation sheet and any proposed advertising material
have received appropriate Research Ethics Committee
(REC), regulatory authorities (MHRA in the UK), and
host institution(s) approval (REC reference: 12/SC/0684
NRES Committee South Central - Oxford B). The Chief
Investigator has submitted and will submit and, where
necessary, obtain approval from the above parties for
all substantial amendments to the original approved
documents.
Participant confidentiality
The trial staff will at all times ensure that the participants’
anonymity is maintained. The participants are identified
only by initials and a participant ID number on the CRF
and any electronic databases. All documents are stored se-
curely and only accessible by trial staff and authorized
personnel. The study complies with the Data Protection
Act, UK 1998, which requires data to be anonymized as
soon as it is practical to do so.
Data handling and record keeping
Data management will be performed in accordance with
PC-CTU standard operating procedure for data manage-
ment. Study-specific procedures are outlined in a data
management plan (DMP) to ensure that high-quality
data are produced for statistical analysis. The DMP was
reviewed and signed by all applicable parties including
the Trial Manager and the Trial Statistician prior to the
first patient being enrolled.
All patients are providing consent using pre-printed
paper consent forms including the unique patient ID.
Prepaid envelopes have been provided to return consent
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the data is being entered by centre trial administrators.
Data collection and management is being conducted
using a secure, web-based system developed in con-
junction with the clinical trials unit. The system incor-
porates data entry and validation rules to reduce data
entry errors, and management functions to facilitate
auditing and data quality assurance. Parallel paper-
based data capture forms will be available to those
patients and clinicians who prefer this option. Data
protection requirements are embedded into the design
of the web-based system and enforced by best practice
trial management procedures. The Clinical Data Manager
will oversee the process of electronic data validation and
manual listings, sending out data clarification forms
(DCFs) when required and following these up until the
queries are resolved.
Once the last patient is enrolled, prior to database lock
a dataset review will be undertaken by the Information
System Manager and Trial Statistician. All critical data
items are 100% checked against original source data doc-
uments to ensure accuracy, and an error rate will be
established across all fields to ensure a consistently ac-
curate dataset.
Patient contact information is being collected at base-
line in paper form and faxed to the relevant study
centre. A copy of the patients contact details consent
form will be sent to the PC-CTU. This information is
being used to contact the patient to collect details for
the primary outcome at 24, 48 and once more up
to 96 hours after the patient has joined the trial, and
for any further follow-up that might be required. The
follow-up contact is being coordinated by a researcher at
the relevant study centre. The contact details are being
stored at the centre separately from all other trial data
and will be anonymized as soon as the required contact
has been completed.
At the conclusion of the trial and after the database
has been locked, all essential documents will be archived
for at least five years. The Chief Investigator is respon-
sible for authorizing the retrieval and disposal of ar-
chived material.
Finance and insurance
The trial is funded by the National Institute for Health
Research School for Primary Care Research, Project
Number 172.
Compensation for harm
Indemnity and/or compensation for negligent harm
arising specifically from an accidental injury for which
the University is legally liable as the Research Sponsor
will be covered by the University of Oxford. The NHS
will owe a duty of care to those undergoing clinicaltreatment, with Trust Indemnity available through the
NHS Litigation Authority Scheme. Indemnity and/or
compensation for non-negligent harm (harm arising specif-
ically from an accidental injury), and occurring as a conse-
quence of the research subjects' participation in the trial
for which the University is the Research Sponsor, will be
covered by the University of Oxford.
Publication policy
The investigators will be involved in reviewing drafts of
the manuscripts, abstracts, press releases and any other
publications arising from the study. Authors will ac-
knowledge that the study was funded by the National In-
stitute for Health Research, NIHR School for Primary
Care Research. Authorship will be determined in accord-
ance with the International Committee of Medical Jour-
nal Editors, ICMJE guidelines and other contributors
will be acknowledged.
Discussion
One of the challenges of designing a trial for an acute
upper respiratory complaint is the fact that we are
recruiting participants on the day that they present to
their GP with a sore throat. There was concern that
this might not leave participants sufficient time to
fully understand the nature of the trial before consent-
ing and receiving the medication. To counteract this
we have developed very streamlined online recruit-
ment procedures for the GPs, and have spent time
with individual practices to ensure that the recruit-
ment process can work within their usual care routine.
These measures have ensured that participants are
having enough time to read the participant informa-
tion sheets outside of the actual clinic appointment so
that when they see the recruiting clinician they will
already have had time to process the information
about the trial and can then simply ask any further
questions they might have.
This trial is evaluating the effectiveness of a single
oral corticosteroid dose in treating sore throat, but it
will also help us to assess current antibiotic prescrib-
ing practices in this situation. We will be able to see
whether delayed antibiotic prescriptions are being given
out, whether these are being used once given and
whether people are simply re-presenting to primary
care or out-of-hours if they are not given an antibiotic
prescription.
Trial status
The trial is currently open and recruiting in all centers
and currently on target. We are aiming to complete re-
cruitment by December 2014 and patient follow-up by
February 2015.
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